Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: Association with severe myelotoxicity

Medical Oncology

Volumn 20, Issue 3, 2003, Pages 291-294

  Bar Sela, Gil ^a,c   Tsalic, Medy ^a   Gaitini, Diana ^a   Steiner, Mariana ^b   Haim, Nissim ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Lin Medical Center   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Advanced gastric cancer; Carboplatin; Myelotoxicity; Oral etoposide; Paclitaxel

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE INFECTION; HOSPITALIZATION; HUMAN; MALE; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMACH CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CARBOPLATIN; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; STOMACH NEOPLASMS; TREATMENT FAILURE;

EID: 0141571156     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:20:3:291     Document Type: Article

References (13)

1. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive are alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587-591.
2. Glimelius B, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163-168.
3. Vanhoefer U, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusion fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18:2648-2657.
4. Ajani JA, et al. Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998; 4:269-271.
5. Garcia AA, et al. Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 2001; 31:275-278.
6. Kollmannsberger C, et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83:458-462.
7. Philip PA, Zalupski MM, Gadgeel S, Hussain M, Shields A. A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Semin Oncol 1997; 24:86-88.
8. Ajani JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am 1999; 5:112-114.
9. Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin and extended-schedule etoposide. J Clin Oncol 1997; 15:2385-2393.
10. Common Toxicity Criteria. In: Investigator's handbook: A manual for participants in clinical trails of investigational agents sponsored by the Division of Cancer Treatment. National Cancer Institute. NIH Pub 93-2770, 1993.
11. Bokemeyer C, et al. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 1997; 24:96-100.
12. Kornek GV, et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erthropoietin in patients with advanced gastric cancer. Br J Cancer 2002; 86:1858-1863.
13. Lokich JJ, et al. Combination paclitaxel, cisplatin and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer 1999; 85:2347-2351.